Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16854
Country/Region: Nigeria
Year: 2014
Main Partner: Center for Clinical Care and Clinical Research
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $9,203,866 Additional Pipeline Funding: N/A

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

The Center for Clinical Care and Clinical Research (CCCRN), with its partner organizations builds upon existing and new strategic partnerships with the public and private sector to support Nigerian health institutions in developing, implementing, monitoring, evaluating and managing HIV/AIDS prevention, care and treatment programs. CCCRN provides HIV/AIDS prevention, care, treatment and laboratory services to HIV infected patients in Imo, Ebonyi and Enugu States called the Service Expansion and Early Detection for Sustainable HIV Care Project (SEEDS). SEEDS applies innovative, sustainable and cost effective strategies that include decentralization, saturation and continuous quality improvement to ensure maintenance of services in existing facilities and rapid expansion to new ones in assigned states. Leveraging on its prior PEPFAR experience with the AIDSRelief and CHARIS projects, CCCRN works in Government, Faith Based and Private institutions at primary, secondary and tertiary levels to expand reach of quality HIV care and treatment services.

The ultimate goal of SEEDS is to reduce mortality and morbidity from HIV in assigned states of Nigeria by ensuring that the following objectives are met

1. The incidence of HIV infections in the target population is reduced.

2.Target population persons living with HIV (PLHIV) and their families receive quality HIV care and treatment services.

3. Service Delivery Facilities (SDFs) have strengthened organizational and technical capacity to provide and support the provision of high quality HIV and AIDS care and treatment services.

4. Service Delivery Partners collaborate with government authorities to sustain HIV and AIDS care and treatment programs.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,024,789
Care: Orphans and Vulnerable Children (HKID) $772,650
Care: TB/HIV (HVTB) $484,066
Care: Pediatric Care and Support (PDCS) $68,346
Laboratory Infrastructure (HLAB) $1,354,999
Strategic Information (HVSI) $135,000
Biomedical Prevention: Blood Safety (HMBL) $30,284
Biomedical Prevention: Injection Safety (HMIN) $49,602
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $766,207
Sexual Prevention: Other Sexual Prevention (HVOP) $221,139
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,185,989
Treatment: Adult Treatment (HTXS) $2,916,614
Treatment: Pediatric Treatment (PDTX) $194,181
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
BS_COLL By: Number of whole blood donations screened for HIV in an NBTS ne2rk laboratory 2015 6,300
BS_COLL By: Number of whole blood donations screened for HIV in an NBTS ne2rk laboratory that are identified as reactive for HIV 2015 140
BS_COLL Number of whole blood collections each year by the NBTS ne2rk 2015 7,000
CARE_CURR Age/sex: <1 Female 2015 141
CARE_CURR Age/sex: <1 Male 2015 61
CARE_CURR Age/sex: 1-4 Female 2015 283
CARE_CURR Age/sex: 1-4 Male 2015 121
CARE_CURR Age/sex: 10-14 Female 2015 565
CARE_CURR Age/sex: 10-14 Male 2015 242
CARE_CURR Age/sex: 15-19 Female 2015 2,510
CARE_CURR Age/sex: 15-19 Male 2015 1,076
CARE_CURR Age/sex: 20-24 Female 2015 8,784
CARE_CURR Age/sex: 20-24 Male 2015 3,765
CARE_CURR Age/sex: 25-49 Female 2015 10,039
CARE_CURR Age/sex: 25-49 Male 2015 4,302
CARE_CURR Age/sex: 5-9 Female 2015 424
CARE_CURR Age/sex: 5-9 Male 2015 182
CARE_CURR Age/sex: 50+ Female 2015 3,765
CARE_CURR Age/sex: 50+ Male 2015 1,613
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 1,413
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 606
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 25,098
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 10,756
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 37,873
CARE_CURR Sum of Age/Sex disaggregates 2015 37,873
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2015 37,873
CARE_NEW Age/sex: <1 Female 2015 14
CARE_NEW Age/sex: <1 Male 2015 6
CARE_NEW Age/sex: 1-4 Female 2015 28
CARE_NEW Age/sex: 1-4 Male 2015 12
CARE_NEW Age/sex: 10-14 Female 2015 56
CARE_NEW Age/sex: 10-14 Male 2015 24
CARE_NEW Age/sex: 15-19 Female 2015 249
CARE_NEW Age/sex: 15-19 Male 2015 107
CARE_NEW Age/sex: 20-24 Female 2015 870
CARE_NEW Age/sex: 20-24 Male 2015 373
CARE_NEW Age/sex: 25-49 Female 2015 994
CARE_NEW Age/sex: 25-49 Male 2015 426
CARE_NEW Age/sex: 5-9 Female 2015 42
CARE_NEW Age/sex: 5-9 Male 2015 18
CARE_NEW Age/sex: 50+ Female 2015 373
CARE_NEW Age/sex: 50+ Male 2015 160
CARE_NEW Aggregated Age/sex: <15 Female 2015 141
CARE_NEW Aggregated Age/sex: <15 Male 2015 60
CARE_NEW Aggregated Age/sex: 15+ Female 2015 2,486
CARE_NEW Aggregated Age/sex: 15+ Male 2015 1,065
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 3,752
CARE_NEW Sum of Age/sex disaggregates 2015 3,752
CARE_NEW Sum of Aggregated Age/sex disaggregates 2015 3,752
GEND_GBV Age: 0-9 2015 9
GEND_GBV Age: 10-14 2015 17
GEND_GBV Age: 15-17 2015 26
GEND_GBV Age: 18-24 2015 15
GEND_GBV Age: 25+ 2015 7
GEND_GBV By PEP service provision (related to sexual violence services provided) 2015 57
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2015 17
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2015 57
GEND_GBV Number of people receiving post-GBV care 2015 74
GEND_GBV Sex: Female 2015 49
GEND_GBV Sex: Male 2015 25
GEND_GBV Sum of Age disaggregates 2015 74
GEND_GBV Sum of Sex disaggregates 2015 74
GEND_NORM By Age: 0-9 2015 103
GEND_NORM By Age: 10-14 2015 103
GEND_NORM By Age: 15-19 2015 248
GEND_NORM By Age: 20-24 2015 620
GEND_NORM By Age: 25+ 2015 992
GEND_NORM By Sex: Female 2015 1,054
GEND_NORM By Sex: Male 2015 1,012
GEND_NORM By type of activity: Community-level 2015 1,446
GEND_NORM By type of activity: Individual 2015 207
GEND_NORM By type of activity: Small Group 2015 413
GEND_NORM Number of people completing an intervention pertaining to gender norms, that meets minimum criteria 2015 2,066
GEND_NORM Sum of Age disaggregates 2015 2,066
GEND_NORM Sum of Sex disaggregates 2015 2,066
HTS_TST Age/sex: <1 Female 2015 1,531
HTS_TST Age/sex: <1 Female 2015 1,531
HTS_TST Age/sex: <1 Male 2015 1,470
HTS_TST Age/sex: <1 Male 2015 1,470
HTS_TST Age/sex: 1-4 Female 2015 1,567
HTS_TST Age/sex: 1-4 Female 2015 1,567
HTS_TST Age/sex: 1-4 Male 2015 1,496
HTS_TST Age/sex: 1-4 Male 2015 1,496
HTS_TST Age/sex: 10-14 Female 2015 1,389
HTS_TST Age/sex: 10-14 Female 2015 1,389
HTS_TST Age/sex: 10-14 Male 2015 1,354
HTS_TST Age/sex: 10-14 Male 2015 1,354
HTS_TST Age/sex: 15-19 Female 2015 33,863
HTS_TST Age/sex: 15-19 Female 2015 33,863
HTS_TST Age/sex: 15-19 Male 2015 15,014
HTS_TST Age/sex: 15-19 Male 2015 15,014
HTS_TST Age/sex: 20-24 Female 2015 96,131
HTS_TST Age/sex: 20-24 Female 2015 96,131
HTS_TST Age/sex: 20-24 Male 2015 31,079
HTS_TST Age/sex: 20-24 Male 2015 31,079
HTS_TST Age/sex: 25-49 Female 2015 201,827
HTS_TST Age/sex: 25-49 Female 2015 201,827
HTS_TST Age/sex: 25-49 Male 2015 97,637
HTS_TST Age/sex: 25-49 Male 2015 97,637
HTS_TST Age/sex: 5-9 Female 2015 623
HTS_TST Age/sex: 5-9 Female 2015 623
HTS_TST Age/sex: 5-9 Male 2015 606
HTS_TST Age/sex: 5-9 Male 2015 606
HTS_TST Age/sex: 50+ Female 2015 3,117
HTS_TST Age/sex: 50+ Female 2015 3,117
HTS_TST Age/sex: 50+ Male 2015 3,028
HTS_TST Age/sex: 50+ Male 2015 3,028
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 5,110
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 4,926
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 334,938
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 146,758
HTS_TST Aggregated Age/sex: <15 Female 2015 5,110
HTS_TST Aggregated Age/sex: <15 Male 2015 4,926
HTS_TST Aggregated Age/sex: 15+ Female 2015 334,938
HTS_TST Aggregated Age/sex: 15+ Male 2015 146,758
HTS_TST By Test Result: Negative 2015 480,559
HTS_TST By Test Result: Negative 2015 480,559
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 491,732
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 491,732
HTS_TST Sum of Age/Sex disaggregates 2015 491,732
HTS_TST Sum of Age/Sex disaggregates 2015 491,732
HTS_TST Sum of Aggregated Age/Sex <15 2015 10,036
HTS_TST Sum of Aggregated Age/Sex <15 2015 10,036
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 481,696
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 481,696
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 491,732
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 491,732
HTS_TST Sum of Test Result disaggregates 2015 491,732
HTS_TST Sum of Test Result disaggregates 2015 491,732
HTS_TST_POS By Test Result: Positive 2015 11,173
HTS_TST_POS By Test Result: Positive 2015 11,173
LAB_ACC By site support type: Direct Service Delivery (DSD) 2015 37
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2015 37
LAB_ACC Sum of Support Type disaggregates 2015 37
OVC_ACC Age: <1 2015 480
OVC_ACC Age: 1-4 2015 1,998
OVC_ACC Age: 10-14 2015 1,918
OVC_ACC Age: 15-17 2015 1,119
OVC_ACC Age: 18+ 2015 240
OVC_ACC Age: 5-9 2015 2,238
OVC_ACC Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services 2015 7,993
OVC_ACC Sex: Female 2015 4,076
OVC_ACC Sex: Male 2015 3,917
OVC_ACC Sum of Age disaggregates 2015 7,993
OVC_ACC Sum of Sex disaggregates 2015 7,993
OVC_SERV Age: <1 2015 1,599
OVC_SERV Age: 1-4 2015 6,660
OVC_SERV Age: 10-14 2015 6,128
OVC_SERV Age: 15-17 2015 3,730
OVC_SERV Age: 18+ 2015 1,066
OVC_SERV Age: 5-9 2015 7,460
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2015 26,643
OVC_SERV Sex: Female 2015 13,588
OVC_SERV Sex: Male 2015 13,055
OVC_SERV Sum of Age disaggregates 2015 26,643
OVC_SERV Sum of Sex disaggregates 2015 26,643
PMTCT_ARV Life-long ART (including Option B+) 2015 1,651
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 150
PMTCT_ARV Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 1,200
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 3,298
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 3,031
PMTCT_ARV Single-dose nevirapine (with or without tail) 2015 30
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 1,091
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 559
PMTCT_ARV Sum of New and Current disaggregates 2015 1,650
PMTCT_ARV Sum of Regimen Type disaggregates 2015 3,031
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 1,651
PMTCT_ARV_NGI Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 150
PMTCT_ARV_NGI Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 1,170
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 3,410
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 3,001
PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) 2015 30
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 1,023
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 628
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 1,651
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 3,001
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 990
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 2,011
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 150
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 3,298
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 3,001
PMTCT_EID Sum of Infant Age disaggregates 2015 3,001
PMTCT_STAT By: Known positives at entry 2015 1,364
PMTCT_STAT By: Number of new positives identified 2015 2,046
PMTCT_STAT Number of new ANC and L&D clients 2015 201,722
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 183,567
PMTCT_STAT Sum of Positives Status disaggregates 2015 3,410
PMTCT_STAT_NGI By: Known positives at entry 2015 1,364
PMTCT_STAT_NGI By: Number of new positives identified 2015 2,046
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 201,722
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 183,567
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 3,410
PP_PREV Age/sex: 10-14 Female 2015 1,137
PP_PREV Age/sex: 10-14 Male 2015 1,093
PP_PREV Age/sex: 15-19 Female 2015 1,365
PP_PREV Age/sex: 15-19 Male 2015 1,311
PP_PREV Age/sex: 20-24 Female 2015 3,413
PP_PREV Age/sex: 20-24 Male 2015 3,279
PP_PREV Age/sex: 25-49 Female 2015 5,119
PP_PREV Age/sex: 25-49 Male 2015 4,918
PP_PREV Age/sex: 50+ Female 2015 341
PP_PREV Age/sex: 50+ Male 2015 328
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2015 22,304
PP_PREV Sum of Age/Sex disaggregates 2015 22,304
PP_PREV Total number of people in the target population 2015 81,032
QI_SITE Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months 2015 32
QI_SITE Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 62
TB_ART Age: 0-4 2015 7
TB_ART Age: 15+ 2015 648
TB_ART Age: 5-14 2015 35
TB_ART Aggregated Age: <15 2015 41
TB_ART Aggregated Age: 15+ 2015 649
TB_ART Female 2015 352
TB_ART Known HIV-positive 2015 297
TB_ART Male 2015 338
TB_ART Newly tested 2015 393
TB_ART Sum of Aggregated Age disaggregates 2015 690
TB_ART Sum of Sex disaggregates 2015 690
TB_ART Sum of Test Status disaggregates 2015 690
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2015 812
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2015 690
TB_SCREEN Age: <1 2015 511
TB_SCREEN Age: 1-4 2015 256
TB_SCREEN Age: 10-14 2015 256
TB_SCREEN Age: 15-19 2015 2,555
TB_SCREEN Age: 20-24 2015 6,388
TB_SCREEN Age: 25-49 2015 14,053
TB_SCREEN Age: 5-9 2015 511
TB_SCREEN Age: 50+ 2015 1,022
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2015 1,533
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2015 24,018
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 37,873
TB_SCREEN Sex: Female 2015 17,886
TB_SCREEN Sex: Male 2015 7,665
TB_SCREEN Sum of Age disaggregates 2015 4,089
TB_SCREEN Sum of Aggregated Age disaggregates 2015 25,551
TB_SCREEN Sum of Sex disaggregates 2015 25,551
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2015 25,551
TX_CURR Age/Sex: <1 Female 2015 64
TX_CURR Age/Sex: <1 Male 2015 72
TX_CURR Age/Sex: 1-4 Female 2015 300
TX_CURR Age/Sex: 1-4 Male 2015 338
TX_CURR Age/Sex: 15+ Female 2015 16,015
TX_CURR Age/Sex: 15+ Male 2015 7,888
TX_CURR Age/Sex: 5-14 Female 2015 545
TX_CURR Age/Sex: 5-14 Male 2015 615
TX_CURR Aggregated Age/Sex: <1 Female 2015 64
TX_CURR Aggregated Age/Sex: <1 Male 2015 72
TX_CURR Aggregated Age/Sex: <15 Female 2015 909
TX_CURR Aggregated Age/Sex: <15 Male 2015 1,025
TX_CURR Aggregated Age/Sex: 15+ Female 2015 16,015
TX_CURR Aggregated Age/Sex: 15+ Male 2015 7,888
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 25,837
TX_CURR Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 7
TX_CURR Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 66
TX_CURR Sum of age/sex disaggregates 2015 1,934
TX_CURR Sum of Aggregated Age/Sex <15 2015 1,934
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 23,903
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 25,837
TX_CURR_NGI Age/Sex: <1 Female 2015 64
TX_CURR_NGI Age/Sex: <1 Male 2015 72
TX_CURR_NGI Age/Sex: 1-4 Female 2015 300
TX_CURR_NGI Age/Sex: 1-4 Male 2015 338
TX_CURR_NGI Age/Sex: 15+ Female 2015 16,015
TX_CURR_NGI Age/Sex: 15+ Male 2015 7,888
TX_CURR_NGI Age/Sex: 5-14 Female 2015 545
TX_CURR_NGI Age/Sex: 5-14 Male 2015 615
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 64
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 72
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 909
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 1,025
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 16,015
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 7,888
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 25,837
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 25,837
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 1,934
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 23,903
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 25,837
TX_NEW Aggregated Grouping by Age: <1 Male 2015 36
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 34
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 225
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 254
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 4,084
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 1,835
TX_NEW By Age/Sex: <1 Female 2015 34
TX_NEW By Age/Sex: <1 Male 2015 36
TX_NEW By Age/Sex: 1-4 Female 2015 45
TX_NEW By Age/Sex: 1-4 Male 2015 51
TX_NEW By Age/Sex: 10-14 Female 2015 90
TX_NEW By Age/Sex: 10-14 Male 2015 104
TX_NEW By Age/Sex: 15-19 Female 2015 613
TX_NEW By Age/Sex: 15-19 Male 2015 275
TX_NEW By Age/Sex: 20-24 Female 2015 1,021
TX_NEW By Age/Sex: 20-24 Male 2015 459
TX_NEW By Age/Sex: 25-49 Female 2015 1,634
TX_NEW By Age/Sex: 25-49 Male 2015 734
TX_NEW By Age/Sex: 5-9 Female 2015 56
TX_NEW By Age/Sex: 5-9 Male 2015 63
TX_NEW By Age/Sex: 50+ Female 2015 817
TX_NEW By Age/Sex: 50+ Male 2015 367
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 6,398
TX_NEW Pregnancy status 2015 327
TX_NEW Sum of Age/Sex disaggregates 2015 6,399
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 6,398
TX_RET Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 348
TX_RET Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 16,542
TX_RET Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 522
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 871
TX_RET Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 16,542
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 17,412
TX_RET Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 8,184
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 20,485
TX_RET_den Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 410
TX_RET_den Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 19,461
TX_RET_den Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 615
TX_RET_den Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,024
TX_RET_den Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 19,461
TX_RET_den Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 963
Cross Cutting Budget Categories and Known Amounts Total: $115,897
Gender: Gender Equality $77,265
Promoting gender-related policies and laws that increase legal protection
Capacity building
Equity in HIV prevention, care, treatment and support
Monitoring and Evaluation
Gender: Gender Based Violence (GBV) $38,632
GBV Prevention
Capacity building
Post GBV Care
Monitoring and Evaluation
Key Issues Identified in Mechanism
enumerations.Malaria (PMI)
Tuberculosis
Family Planning